-
Breaking the Dilemma of Margins in Breast-Conserving Surgery: SHAVE Series Research Confirms CSM Significantly Reduces Re-excision Rates, but Long-term Survival Benefit Remains Dominated by Radiotherapy
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Anees B. Chagpar, a Professor of Surgery at the Yale School of Medicine, delivered an important special report titled “Does resection of cavity shave margins impact survival in breast cancer patients?”. Based on the famous SHAVE and SHAVE2 randomized controlled trials, the report…
-
EHA Reflections | Dr. Jing Pan: Novel Nanobody-Based Dual-Epitope CD5 CAR-T Uses Speed to Redefine T-ALL Immunotherapy
Treatment options remain extremely limited for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who relapse after CD7 CAR-T therapy. Although previous studies of humanized CD5 CAR-T cells demonstrated encouraging antitumor activity, long-term follow-up revealed a significant safety challenge: a high incidence of severe and sometimes fatal infections.
-
EHA Reflections | Professors Huilai Zhang and Junlei Jia: Decoding the Biological Landscape of Primary Breast DLBCL to Advance Precision Risk Stratification and Long-Term Disease Management
Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal subtype of DLBCL characterized by unique clinicopathological features and an increased risk of central nervous system (CNS) relapse. Due to its low incidence, comprehensive investigations into its biological characteristics have remained limited.
-
EHA Reflections | Professor Fengkui Zhang: Oral Factor B Inhibitor Shows Superior Efficacy and May Redefine First-Line Treatment for PNH
Complement C5 inhibitors have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and remain the current standard first-line therapy. However, despite effective control of intravascular hemolysis, many patients continue to experience persistent anemia, limited hemoglobin recovery, and clinically significant extravascular hemolysis, leaving substantial unmet medical needs.
-
EHA Reflections | Professor Yizhen Li’s Plenary Session Presentation: CD5 Inhibition as a Universal Strategy to Broadly Enhance T-Cell Engager Antitumor Activity
At the highly anticipated Plenary Session of the 2026 European Hematology Association (EHA) Congress, Professor Yizhen Li from the Children’s Hospital of Soochow University presented his team’s original research findings.
-
EHA Reflections | Professor Heng Mei’s Team Reports Landmark LBA Study: BCMA CAR-T–Mediated Immune Reset Opens a New Era of Functional Cure for Refractory ITP
Refractory immune thrombocytopenia (ITP) remains a major clinical challenge. Characterized by frequent relapses, chronic treatment dependence, and limited curative options, many patients struggle to achieve durable remission despite multiple lines of therapy.
-
Director Zhihui Li: Two Original Studies Redefine Post-Transplant Prognosis and Highlight Five Key Advances in Hematopoietic Transplantation
At the 2026 European Hematology Association (EHA) Congress, the team led by Director Zhihui Li from Beijing GoBroad Boren Hospital presented two studies selected for poster presentation.
Connecting Medical Expertise through Media